The 24-month follow-up data from the randomized phase 1/2 trial of ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM) was announced 10 June 2021 (see press release here). It showed that the median overall survival will be in the range of 21.9 to 25.0 months for first-line ONCOS-102-treated patients in the randomized group (n=8).
More:
prnewswire.com/news-releases/targovax-releases-presentations-of-oncos-102-mesothelioma-24-month-data-301311388.html
No comments:
Post a Comment